Micronised progesterone

Green-G

Brand Name(s):Utrogestan

Indication:Hormone replacement therapy (HRT)

Rationale:

Considered:May-21

Review Date:May-26

Comments:
Utrogestan is indicated for adjunctive use with estrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT).

In women receiving estrogen replacement therapy there is an increased risk of endometrial cancer which can be countered by progesterone administration.
The recommended dose is 200 mg daily at bedtime, for twelve days in the last half of each therapeutic cycle (beginning on Day 15 of the cycle and ending on Day 26). Withdrawal bleeding may occur in the following week.
Alternatively 100 mg can be given at bedtime from Day 1 to Day 25 of each therapeutic cycle, withdrawal bleeding being less with this treatment schedule.